Hearing loss in children treated for multidrug-resistant tuberculosis - 06/03/13


Summary |
Objective |
The aminoglycosides and polypeptides are vital drugs for the management of multidrug-resistant (MDR) tuberculosis (TB). Both classes of drug cause hearing loss. We aimed to determine the extent of hearing loss in children treated for MDR-TB.
Methods |
In this retrospective study, children (<15 years) admitted to Brooklyn Chest Hospital, Cape Town, South Africa, from January 2009 until December 2010, were included if treated for MDR-TB with injectable drugs. Hearing was assessed and classified using audiometry and otoacoustic emissions.
Results |
Ninety-four children were included (median age: 43 months). Of 93 tested, 28 (30%) were HIV-infected. Twenty-three (24%) children had hearing loss. Culture-confirmed, as opposed to presumed, diagnosis of TB was a risk factor for hearing loss (OR: 4.12; 95% CI: 1.13–15.0; p = 0.02). Seven of 11 (64%) children classified as having hearing loss using audiometry had progression of hearing loss after finishing the injectable drug.
Conclusions |
Hearing loss is common in children treated for MDR-TB. Alternative drugs are required for the treatment of paediatric MDR-TB.
Le texte complet de cet article est disponible en PDF.Keywords : Hearing, Audiology, Tuberculosis, Multidrug-resistant, Resistant, Ototoxicity, Children, Paediatric
Abbreviations : MDR, DR, TB, WHO, PTA, OAE, DPOAE, BCH, IM, ASHA, OR, CI, IQR
Plan
Vol 66 - N° 4
P. 320-329 - avril 2013 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?